Meet us at…
Latest news
Laurie Perdigon (1) , Manon Barthe (1) , Hanan Osman-Ponchet (1) , Agnes Choppin (2) , Franck Chiappini (2) Human precision-cut lung slices (hPCLS) are a promising ex vivo model for respiratory research. These thin, precisely-cut tissues, obtained from fresh lungs using a vibrating microtome, retain the native 3D architecture [...]
6 November 2024
Manon Barthe (1) , Laurie Perdigon (1) , Hanan Osman-Ponchet (1) , Agnès Choppin (2) , Franck Chiapini (2) Pulmonary fibrosis is a progressive, restrictive lung disease characterized by scarring and stiffening of lung tissue, ultimately leading to respiratory failure. This condition is driven by the excessive proliferation and migration [...]
6 November 2024
Clerapliq - Topical Treatment with a New Matrix Therapy Agent Abdelouahab Aifa, Julie Gueudry, Alexandre Portmann, Agn`es Delcampe, and Marc Muraine PURPOSE. Neurotrophic keratopathy is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, possibly leading to perforation. We aimed to assess the efficacy and tolerance [...]
12 May 2022
Clerapliq -Prise en charge médicale des ulcères cornéens avec RGTA Cas clinique - L'Essentiel Bertrand Michaud - Docteur vétérinaire Les ulcères cornéens sont des affections fréquemment rencontrées en pratique vétérinaire quotidienne. Leur trai- tement passe par la mise en évidence de l’origine de la lésion. Ainsi, le traitement devra [...]
12 May 2022
OTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).
25 March 2022
OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..
10 February 2022
OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.
8 October 2021
